BioDelivery Sciences International Inc
NASDAQ:BDSI
Intrinsic Value
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of BDSI.
BioDelivery Sciences International Inc's market capitalization is 552.6m USD.
BDSI stock price is 5.59 USD.
BDSI.
BDSI. Open DCF Valuation
BDSI. Open Relative Valuation
BDSI.
BDSI's Revenue has grown by 7% over the past 12 months.
BDSI has positive three-year average ROIC (Return on Invested Capital): 12%. The company is efficient at using invested capital to generate operating income.
BDSI has positive Operating Income for the last twelve months.
BDSI has positive Free Cash Flow for the last twelve months.
BDSI has positive Net Income for the last twelve months.
BDSI's ROE (Return on Equity) has significantly increased in the last 3 years from 28% to 57%.
BDSI's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from 29% to 65%.
BDSI's ROE (Return on Equity) for the past 12 months is very high and is equal to 57%.
BDSI's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 65%.
BDSI's long-term assets (325m USD) exceed its long-term liabilties (137m USD).
BDSI has negative Net Debt. This means that the company has more cash and short-term investments (114m USD) than debt (54m USD).
BDSI's short-term assets (202m USD) exceed its short-term liabilties (82m USD).
BDSI has positive Gross Profit for the last twelve months.
BDSI's D/E (Debt to Equity) is very low and is equal to 0.29.
BDSI's Altman Z-Score is very low and is equal to 1.15.
BDSI generates enough operating income (37m USD) to cover interest payments on its debt (7m USD).
BDSI has negative three-year average ROE (Return on Equity): -23%. The company is not efficient at transforming stockholders' equity into net income.
Fundamental Analysis
BioDelivery Sciences International Inc
Balance Sheet Decomposition
BioDelivery Sciences International Inc
| Current Assets | 202.1m |
| Cash & Short-Term Investments | 114.3m |
| Receivables | 56.9m |
| Other Current Assets | 30.9m |
| Non-Current Assets | 122.5m |
| PP&E | 1.7m |
| Intangibles | 61.5m |
| Other Non-Current Assets | 59.2m |
| Current Liabilities | 82.4m |
| Accounts Payable | 8.1m |
| Accrued Liabilities | 69m |
| Other Current Liabilities | 5.3m |
| Non-Current Liabilities | 54.4m |
| Long-Term Debt | 54.2m |
| Other Non-Current Liabilities | 219k |
Earnings Waterfall
BioDelivery Sciences International Inc
|
Revenue
|
166.7m
USD
|
|
Cost of Revenue
|
-23.4m
USD
|
|
Gross Profit
|
143.3m
USD
|
|
Operating Expenses
|
-106.2m
USD
|
|
Operating Income
|
37.1m
USD
|
|
Other Expenses
|
47.7m
USD
|
|
Net Income
|
84.9m
USD
|
Free Cash Flow Analysis
BioDelivery Sciences International Inc
BDSI Profitability Score
Profitability Due Diligence
BioDelivery Sciences International Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
BioDelivery Sciences International Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
BDSI Solvency Score
Solvency Due Diligence
BioDelivery Sciences International Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
BioDelivery Sciences International Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BDSI Price Targets Summary
BioDelivery Sciences International Inc
Ownership
BDSI Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BDSI Price
BioDelivery Sciences International Inc
| Average Annual Return | -1.5% |
| Standard Deviation of Annual Returns | 40.98% |
| Max Drawdown | -64% |
| Market Capitalization | 552.6m USD |
| Shares Outstanding | 103 229 000 |
| Percentage of Shares Shorted | 4.6% |
Company Profile
BioDelivery Sciences International Inc
Country
Industry
Market Cap
Dividend Yield
Description
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
You don't have any saved screeners yet
